FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220716687> ?p ?o ?g. }

• W4220716687 endingPage "741" @default.
• W4220716687 startingPage "732" @default.
• W4220716687 abstract "Hypofractionated radiation therapy has been safely implemented in the treatment of early-stage non-small cell lung cancer (NSCLC) but not locally advanced NSCLC owing to prohibitive toxicities with photon therapy. Proton therapy, however, may allow for safe delivery of hypofractionated radiation therapy. We sought to determine whether hypofractionated proton therapy with concurrent chemotherapy improves overall survival.The Proton Collaborative Group conducted a phase 1/2 single-arm nonrandomized prospective multicenter trial from 2013 through 2018. We received consent from 32 patients, of whom 28 were eligible for on-study treatment. Patients had stage II or III unresectable NSCLC (based on the 7th edition of the American Joint Committee on Cancer's staging manual) and received hypofractionated proton therapy at 2.5 to 4 Gy per fraction to a total 60 Gy with concurrent platin-based doublet chemotherapy. The primary outcome was 1-year overall survival comparable to the 62% reported for the Radiation Therapy Oncology Group (RTOG) 9410 trial.The trial closed early owing to slow accrual, in part, from a competing trial, RTOG 1308. Median patient age was 70 years (range, 50-86 years). Patients were predominantly male (n = 20), White (n = 23), and prior smokers (n = 27). Most had stage III NSCLC (n = 22), 50% of whom had adenocarcinoma. After a median follow-up of 31 months, the 1- and 3-year overall survival rates were 89% and 49%, respectively, and progression-free survival rates were 58% and 32%, respectively. No acute grade ≥3 esophagitis occurred. Only 14% developed a grade ≥3 radiation-related pulmonary toxic effect.Hypofractionated proton therapy delivered at 2.5 to 3.53 Gy per fraction to a total 60 Gy with concurrent chemotherapy provides promising survival, and additional examination through larger studies may be warranted." @default.
• W4220716687 created "2022-04-03" @default.
• W4220716687 creator A5009490529 @default.
• W4220716687 creator A5015910445 @default.
• W4220716687 creator A5016840607 @default.
• W4220716687 creator A5022932491 @default.
• W4220716687 creator A5023899503 @default.
• W4220716687 creator A5024759766 @default.
• W4220716687 creator A5034586842 @default.
• W4220716687 creator A5046901718 @default.
• W4220716687 creator A5055302998 @default.
• W4220716687 creator A5058130022 @default.
• W4220716687 creator A5067536094 @default.
• W4220716687 creator A5072085443 @default.
• W4220716687 date "2022-07-01" @default.
• W4220716687 modified "2023-10-15" @default.
• W4220716687 title "Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial" @default.
• W4220716687 cites W1968899146 @default.
• W4220716687 cites W1984068275 @default.
• W4220716687 cites W2040399379 @default.
• W4220716687 cites W2058344766 @default.
• W4220716687 cites W2078763031 @default.
• W4220716687 cites W2104011039 @default.
• W4220716687 cites W2119575650 @default.
• W4220716687 cites W2121138562 @default.
• W4220716687 cites W2141498930 @default.
• W4220716687 cites W2142595173 @default.
• W4220716687 cites W2143715924 @default.
• W4220716687 cites W2152939220 @default.
• W4220716687 cites W2159751658 @default.
• W4220716687 cites W2179171978 @default.
• W4220716687 cites W2313268710 @default.
• W4220716687 cites W2336177995 @default.
• W4220716687 cites W2345933175 @default.
• W4220716687 cites W2595048933 @default.
• W4220716687 cites W2595526561 @default.
• W4220716687 cites W2616226761 @default.
• W4220716687 cites W2737087640 @default.
• W4220716687 cites W2781965877 @default.
• W4220716687 cites W2893824814 @default.
• W4220716687 cites W2995072671 @default.
• W4220716687 cites W3015090990 @default.
• W4220716687 cites W3017808685 @default.
• W4220716687 cites W3094213671 @default.
• W4220716687 cites W3175711134 @default.
• W4220716687 cites W3196027805 @default.
• W4220716687 doi "https://doi.org/10.1016/j.ijrobp.2022.03.005" @default.
• W4220716687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35306151" @default.
• W4220716687 hasPublicationYear "2022" @default.
• W4220716687 type Work @default.
• W4220716687 citedByCount "4" @default.
• W4220716687 countsByYear W42207166872022 @default.
• W4220716687 countsByYear W42207166872023 @default.
• W4220716687 crossrefType "journal-article" @default.
• W4220716687 hasAuthorship W4220716687A5009490529 @default.
• W4220716687 hasAuthorship W4220716687A5015910445 @default.
• W4220716687 hasAuthorship W4220716687A5016840607 @default.
• W4220716687 hasAuthorship W4220716687A5022932491 @default.
• W4220716687 hasAuthorship W4220716687A5023899503 @default.
• W4220716687 hasAuthorship W4220716687A5024759766 @default.
• W4220716687 hasAuthorship W4220716687A5034586842 @default.
• W4220716687 hasAuthorship W4220716687A5046901718 @default.
• W4220716687 hasAuthorship W4220716687A5055302998 @default.
• W4220716687 hasAuthorship W4220716687A5058130022 @default.
• W4220716687 hasAuthorship W4220716687A5067536094 @default.
• W4220716687 hasAuthorship W4220716687A5072085443 @default.
• W4220716687 hasBestOaLocation W42207166871 @default.
• W4220716687 hasConcept C121608353 @default.
• W4220716687 hasConcept C126322002 @default.
• W4220716687 hasConcept C143998085 @default.
• W4220716687 hasConcept C146357865 @default.
• W4220716687 hasConcept C151730666 @default.
• W4220716687 hasConcept C155806632 @default.
• W4220716687 hasConcept C2776256026 @default.
• W4220716687 hasConcept C2779134260 @default.
• W4220716687 hasConcept C2779244869 @default.
• W4220716687 hasConcept C2779920096 @default.
• W4220716687 hasConcept C2781182431 @default.
• W4220716687 hasConcept C43270747 @default.
• W4220716687 hasConcept C509974204 @default.
• W4220716687 hasConcept C71924100 @default.
• W4220716687 hasConcept C86803240 @default.
• W4220716687 hasConceptScore W4220716687C121608353 @default.
• W4220716687 hasConceptScore W4220716687C126322002 @default.
• W4220716687 hasConceptScore W4220716687C143998085 @default.
• W4220716687 hasConceptScore W4220716687C146357865 @default.
• W4220716687 hasConceptScore W4220716687C151730666 @default.
• W4220716687 hasConceptScore W4220716687C155806632 @default.
• W4220716687 hasConceptScore W4220716687C2776256026 @default.
• W4220716687 hasConceptScore W4220716687C2779134260 @default.
• W4220716687 hasConceptScore W4220716687C2779244869 @default.
• W4220716687 hasConceptScore W4220716687C2779920096 @default.
• W4220716687 hasConceptScore W4220716687C2781182431 @default.
• W4220716687 hasConceptScore W4220716687C43270747 @default.
• W4220716687 hasConceptScore W4220716687C509974204 @default.
• W4220716687 hasConceptScore W4220716687C71924100 @default.
• W4220716687 hasConceptScore W4220716687C86803240 @default.
• W4220716687 hasIssue "4" @default.

• next